The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes

Transplant Immunology

Volumn 30, Issue 1, 2014, Pages 24-29

  Banasik, Mirosław ^a   Boratyńska, Maria ^a   Kościelska Kasprzak, Katarzyna ^a   Krajewska, Magdalena ^a   Mazanowska, Oktawia ^a   Kamińska, Dorota ^a   Bartoszek, Dorota ^a   Zabińska, Marcelina ^a   Myszka, Marta ^a   Nowakowska, Beata ^b   Hałoń, Agnieszka ^a   Dawiskiba, Tomasz ^a   Chudoba, Paweł ^a   Klinger, Marian ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Antibody mediated rejection; ETAR Abs; Humoral rejection; Non HLA antibodies; Renal transplant injury; Renal transplantation

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN; ENDOTHELIN 1 TYPE A RECEPTOR; ENDOTHELIN 1 TYPE A RECEPTOR ANTIBODY; HLA ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECEPTOR ANTIBODY; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; ALLOANTIBODY; ENDOTHELIN A RECEPTOR; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ARTERITIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HUMORAL IMMUNITY; IMMUNE STATUS; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SCREENING; ACUTE DISEASE; ADULT; BLOOD; CELLULAR IMMUNITY; GRAFT OCCLUSION; GRAFT REJECTION; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; CREATININE; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ENDOTHELIN A; TREATMENT OUTCOME;

EID: 84891828354     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.10.007     Document Type: Article

References (52)

1. Tait B.D., Susal C., Gebel H.M., Nickerson P.W., Zachary A.A., Claas F.H., et al. Consensus guidelines on the testing and clinical management issues associated with HLA and Non-HLA antibodies in transplantation. Transplantation 2013 Jan 15, 95(1):19-47.
2. Terasaki P.I. Humoral theory of transplantation. Am J Transplant 2003 Jun, 3(6):665-673.
3. Cai J., Terasaki P.I. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 2005 Apr, 66(4):334-342.
4. Banasik M., Boratynska M., Nowakowska B., Halon A., Koscielska-Kasprzak K., Drulis-Fajdasz D., et al. Variability in donor-specific alloantibody production after transplantation. Transplant Proc 2007 Nov, 39(9):2715-2717.
5. Banasik M., Boratynska M., Koscielska-Kasprzak K., Mazanowska O., Krajewska M., Zabinska M., et al. The Impact of De Novo donor-specific Anti-Human Leukocyte Antigen Antibodies on 5-Year Renal Transplant Outcome. Transplant Proc 2013 May, 45(4):1449-1452.
6. Crespo M., Torio A., Mas V., Redondo D., Perez-Saez M.J., Mir M., et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: Does C1q-fixation matter?. Transpl Immunol 2013 Dec, 29(1-4):28-33.
7. Fidler S.J., Irish A.B., Lim W., Ferrari P., Witt C.S., Christiansen F.T. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death. Transpl Immunol 2013 Jun, 28(4):148-153.
8. Angaswamy N., Tiriveedhi V., Sarma N.J., Subramanian V., Klein C., Wellen J., et al. Interplay between Immune responses to HLA and Non-HLA self-antigens in allograft rejection. Hum Immunol 2013, 74(11):1478-1485. [Jul 19]. 10.1016/j.humimm.2013.07.002.
9. Yard B., Spruyt-Gerritse M., Claas F., Thorogood J., Bruijn J.A., Paape M.E., et al. The clinical significance of allospecific antibodies against endothelial cells detected with an antibody-dependent cellular cytotoxicity assay for vascular rejection and graft loss after renal transplantation. Transplantation 1993 Jun, 55(6):1287-1293.
10. Dragun D., Catar R., Philippe A. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transplant 2013 Aug, 18(4):430-435.
11. Dragun D., Brasen J.H., Schonemann C., Fritsche L., Budde K., Neumayer H.H., et al. Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. Transplant Proc 2003 Sep, 35(6):2104-2105.
12. Reinsmoen N.L., Lai C.H., Heidecke H., Haas M., Cao K., Ong G., et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010, 90(12):1473-1477. [Dec 27].
13. Banasik M., Boratynska M., Koscielska-Kasprzak K., Mazanowska O., Bartoszek D., Zabinska M., et al. Long-term follow-up of non-HLA and anti-HLA antibodies: incidence and importance in renal transplantation. Transplant Proc 2013 May, 45(4):1462-1465.
14. Hiemann N.E., Meyer R., Wellnhofer E., Schoenemann C., Heidecke H., Lachmann N., et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012 Nov 15, 94(9):919-924.
15. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988 Mar 31, 332(6163):411-415.
16. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989 Apr, 86(8):2863-2867.
17. Dragun D., Hegner B. Non-HLA antibodies post-transplantation: clinical relevance and treatment in solid organ transplantation. Contrib Nephrol 2009, 162:129-139.
18. Mizutani K., Terasaki P., Rosen A., Esquenazi V., Miller J., Shih R.N., et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005 Sep, 5(9):2265-2272.
19. Schneider M.P., Boesen E.I., Pollock D.M. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007, 47:731-759. [PubMed PMID: 17002597.].
20. Zhang Q., Cecka J.M., Gjertson D.W., Ge P., Rose M.L., Patel J.K., et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation 2011, 91(10):1153-1158. [May 27].
21. Hankey K.G., Drachenberg C.B., Papadimitriou J.C., Klassen D.K., Philosophe B., Bartlett S.T., et al. MIC expression in renal and pancreatic allografts. Transplantation 2002, 73(2):304-306. [Jan 27].
22. Leong H.S., Mahesh B.M., Day J.R., Smith J.D., McCormack A.D., Ghimire G., et al. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor. J Leukoc Biol 2008 Feb, 83(2):263-271.
23. Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352(6):558-569. [Feb 10].
24. Goers T.A., Ramachandran S., Aloush A., Trulock E., Patterson G.A., Mohanakumar T. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol 2008, 180(7):4487-4494. [Apr 1, PubMed PMID: 18354170.].
25. Warraich R.S., Pomerance A., Stanley A., Banner N.R., Dunn M.J., Yacoub M.H. Cardiac myosin autoantibodies and acute rejection after heart transplantation in patients with dilated cardiomyopathy. Transplantation 2000, 69(8):1609-1617. [Apr 27].
26. Burlingham W.J., Love R.B., Jankowska-Gan E., Haynes L.D., Xu Q., Bobadilla J.L., et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007 Nov, 117(11):3498-3506.
27. Solez K., Colvin R.B., Racusen L.C., Sis B., Halloran P.F., Birk P.E., et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007 Mar, 7(3):518-526.
28. Solez K., Racusen L.C. The Banff classification revisited. Kidney Int 2013 Feb, 83(2):201-206.
29. Mao Q., Terasaki P.I., Cai J., Briley K., Catrou P., Haisch C., et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007 Apr, 7(4):864-871.
30. Banasik M., Boratynska M., Nowakowska B., Halon A., Koscielska-Kasprzak K., Drulis-Fajdasz D., et al. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients. Transplant Proc 2007 Nov, 39(9):2718-2720.
31. Banasik M., Klinger M. Chronic allograft nephropathy-immunologic and nonimmunologic factors. Ann transplant 2006, 11(1):7-10.
32. Kaminska D., Tyran B., Mazanowska O., Rabczynski J., Szyber P., Patrzalek D., et al. Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reverse-transcription polymerase chain reaction analysis. Transplantation 2007, 84(9):1118-1124. [Nov 15].
33. Kedzierski R.M., Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001, 41:851-876.
34. Dragun D. Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol Dial Transplant 2007 Jul, 22(7):1819-1822.
35. Giral M., Foucher Y., Dufay A., Van Huyen J.P., Renaudin K., Moreau A., et al. Pretransplant Sensitization Against Angiotensin II Type 1 Receptor Is a Risk Factor for Acute Rejection and Graft Loss. Am J Transplant 2013, 13(10):2567-2576. [Aug 6].
36. Taniguchi M., Rebellato L.M., Cai J., Hopfield J., Briley K.P., Haisch C.E., et al. Higher Risk of Kidney Graft Failure in the Presence of Anti-Angiotensin II Type-1 Receptor Antibodies. Am J Transplant 2013, 13(10):2577-2589. [Aug 13].
37. Win T.S., Pettigrew G.J. Humoral autoimmunity and transplant vasculopathy: when allo is not enough. Transplantation 2010, 90(2):113-120. [Jul 27].
38. Jurcevic S., Ainsworth M.E., Pomerance A., Smith J.D., Robinson D.R., Dunn M.J., et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001, 71(7):886-892. [Apr 15].
39. Joosten S.A., van Dixhoorn M.G., Borrias M.C., Benediktsson H., van Veelen P.A., van Kooten C., et al. Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 2002 Apr, 160(4):1301-1310.
40. Bordron A., Dueymes M., Levy Y., Jamin C., Leroy J.P., Piette J.C., et al. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest 1998, 101(10):2029-2035. May 15 PubMed PMID: 9593758.
41. Bohana-Kashtan O., Ziporen L., Donin N., Kraus S., Fishelson Z. Cell signals transduced by complement. Mol Immunol 2004 Jul, 41(6-7):583-597.
42. Zhang X., Reed E.F. Effect of antibodies on endothelium. Am J Transplant 2009 Nov, 9(11):2459-2465. [PubMed PMID: 19775314. Epub 2009/09/25. eng].
43. Jin Y.P., Korin Y., Zhang X., Jindra P.T., Rozengurt E., Reed E.F. RNA interference elucidates the role of focal adhesion kinase in HLA class I-mediated focal adhesion complex formation and proliferation in human endothelial cells. J Immunol 2007, 178(12):7911-7922. [Jun 15].
44. Coupel S., Leboeuf F., Boulday G., Soulillou J.P., Charreau B. RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: an alloimmune mechanism of chronic allograft nephropathy. J Am Soc Nephrol 2004 Sep, 15(9):2429-2439.
45. Jindra P.T., Jin Y.P., Rozengurt E., Reed E.F. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008, 180(4):2357-2366. [Feb 15].
46. Hattori T., Shimokawa H., Higashi M., Hiroki J., Mukai Y., Kaibuchi K., et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res 2004, 94(1):46-52. [Jan 9].
47. Hiemann N.E., Wellnhofer E., Knosalla C., Lehmkuhl H.B., Stein J., Hetzer R., et al. Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies. Circulation 2007, 116(11):1274-1282. [Sep 11].
48. Hiemann N.E., Musci M., Wellnhofer E., Meyer R., Hetzer R. Light microscopic biopsy findings after heart transplantation and possible links to development of graft vessel disease. Transplant Proc 1999, 31(1-2):149-151. Feb-Mar.
49. Jurewicz M., McDermott D.H., Sechler J.M., Tinckam K., Takakura A., Carpenter C.B., et al. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007 Apr, 18(4):1093-1102.
50. Orth S.R., Odoni G., Karkoszka H., Ogata H., Viedt C., Amann K., et al. Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models. Nephrol Dial Transplant 2003 Jan, 18(1):62-69.
51. Adams J., Odoni G., Ogata H., Viedt C., Amann K., Ritz E., et al. Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant nephropathy in a 'Fisher-to-Lewis' rat model. Nephrol Dial Transplant 2002 May, 17(5):780-787.
52. Nath D.S., Basha H.I., Mohanakumar T. Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection. Curr Opin Organ Transplant 2010 Feb, 15(1):16-20.